Loading clinical trials...

Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life

NCT00126997•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.

Eligibility

Age

0 - 1 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•A male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination.

Exclusion Criteria

•History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial
•Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination

Locations (54)

GSK Investigational Site

Espoo, Finland

GSK Investigational Site

Lahti, Finland

GSK Investigational Site

Oulu, Finland

GSK Investigational Site

Pori, Finland

GSK Investigational Site

Tampere, Finland

GSK Investigational Site

Turku, Finland

GSK Investigational Site

Vantaa, Finland

GSK Investigational Site

Bayreuth, Bavaria, Germany

GSK Investigational Site

Bindlach, Bavaria, Germany

GSK Investigational Site

Bobingen, Bavaria, Germany

Key Dates

Start Date

May 1, 2005

Primary Completion Date

November 1, 2005

Completion Date

November 1, 2005

Last Updated

September 21, 2016

Enrollment

1,439

ACTUAL participants

Conditions

MumpsRubellaMeaslesVaricella

Interventions

Measles, Mumps, Rubella and Chickenpox (live vaccine)

BIOLOGICAL

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

NCT07112846

ExanthemaDengue Fever+3 more

View study

COMPLETEDPHASE4

Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children

NCT03460002

Measles VaccinationOral Polio Vaccine+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 21, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Inclusion Criteria

Exclusion Criteria

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children

Co-administration Study of OCV, TCV and MR

Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control Trial

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants